Publikationen

2023

•  EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells. Schumacher N, Thomsen I, Brundert F, Hejret V, Düsterhöft S, Tichý B, Schmidt-Arras D, Voss M, Rose-John S.Biochim Biophys Acta Mol Cell Res. 2023 Jun 2;1870(7):119489
•  Cell-Autonomous Constitutive gp130 Signaling in T Cells Amplifies TH17 Cell Responses and Causes Severe Lung Inflammation. Heinig LC, Huth EVM, Yan K, Schumacher N, Nawrocki M, Lory NC, Bradtke P, Bertram T, Rattay G, Schmid J, Huber S, Wiech T, Schmidt-Arras D, Rose-John S, Mittrücker HW. J Immunol. 2023 Jun 1;210(11):1717-1727

2022

•  Tetraspanin 8 Subfamily Members Regulate Substrate-Specificity of a Disintegrin and Metalloprotease 17. Müller M, Saunders C, Senftleben A, Heidbuechel JPW, Halwachs B, Bolik J, Hedemann N, Röder C, Bauerschlag D, Rose-John S, Schmidt-Arras D. Cells. 2022 Aug 29;11(17):2683
•  Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. Rosenberg N, Van Haele M, Lanton T, Brashi N, Bromberg Z, Adler H, Giladi H, Peled A, Goldenberg DS, Axelrod JH, Simerzin A, Chai C, Paldor M, Markezana A, Yaish D, Shemulian Z, Gross D, Barnoy S, Gefen M, Amran O, Claerhout S, Fernández-Vaquero M, García-Beccaria M, Heide D, Shoshkes-Carmel M, Schmidt Arras D, Elgavish S, Nevo Y, Benyamini H, Tirnitz-Parker JEE, Sanchez A, Herrera B, Safadi R, Kaestner KH, Rose-John S, Roskams T, Heikenwalder M, Galun E. J Hepatol. 2022 Dec;77(6):1631-1641
•  Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. Bolik J, Krause F, Stevanovic M, Gandraß M, Thomsen I, Schacht SS, Rieser E, Müller M, Schumacher N, Fritsch J, Wichert R, Galun E, Bergmann J, Röder C, Schafmayer C, Egberts JH, Becker-Pauly C, Saftig P, Lucius R, Schneider-Brachert W, Barikbin R, Adam D, Voss M, Hitzl W, Krüger A, Strilic B, Sagi I, Walczak H, Rose-John S, Schmidt-Arras D. J Exp Med. 2022 Jan 3;219(1):e20201039

2021

•  Roles for ADAM17 in TNF-R1 Mediated Cell Death and Survival in Human U937 and Jurkat Cell. Fritsch J, Frankenheim J, Marischen L, Vadasz T, Troeger A, Rose-John S, Schmidt-Arras D and Schneider-Brachert W. Cells. 2021; 10(11):3100
•  Mediators of liver inflammation and carcinogenesis. Herkel J, Schmidt-Arras D. Semin Immunopathol. 2021 Aug;43(4):477-479.
•  Endosomes as Signaling Platforms for IL-6 Family Cytokine Receptors. Schmidt-Arras D, Rose-John S. Front Cell Dev Biol. 2021 Jun 1;9:688314.
•  The two facets of gp130 signalling in liver tumorigenesis. Schmidt-Arras D, Galun E, Rose-John S. Semin Immunopathol. 2021 Aug;43(4):609-624.
•   Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome. Chen YH, Zastrow DB, Metcalfe RD, Gartner L, Krause F, Morton CJ, Marwaha S, Fresard L, Huang Y, Zhao C, McCormack C, Bick D, Worthey EA, Eng CM, Gold J, Undiagnosed Diseases Network, Montgomery SB, Fisher PG, Ashley EA, Wheeler MT, Parker MW, Shanmugasundaram V, Putoczki TL, Schmidt-Arras D*, Laurence A*, Bernstein JA*, Griffin MDW*, Uhlig HH*. J Allergy Clin Immunol. 2021 Mar 23:S0091-6749(21)00471-1
•  Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice. Schumacher N, Yan K, Gandraß M, Müller M, Krisp C, Häsler R, Carambia A, Nofer JR, Bernardes JP, Khouja M, Thomsen I, Chalupsky K, Bolik J, Hölscher C, Wunderlich T, Herkel J, Rosenstiel P, Schramm C, Schlüter H, Renné T, Mittrücker HW, Rose-John S, Schmidt-Arras D. J Hepatol. 2021 Feb;74(2):407-418

2020

•  Novel Approaches to Target Mutant FLT3 Leukaemia. Müller JP, Schmidt-Arras D. Cancers (Basel). 2020 Sep 29;12(10):2806
•  ADAM-Mediated Signalling Pathways in Gastrointestinal Cancer Formation. Schumacher N, Rose-John S, Schmidt-Arras D. Int J Mol Sci. 2020 Jul 20;21(14):5133
•   Mislocalisation of Activated Receptor Tyrosine Kinases – Challenges for Cancer Therapy Schmidt-Arras D*, Böhmer FD. Trends Mol Med. 2020 Sep;26(9):833-847
•  A variant in IL6ST with a selective IL-11 signaling defect in human and mouse. Schwerd T, Krause F, Twigg SRF, Aschenbrenner D, Chen YH, Borgmeyer U, Müller M, Manrique S, Schumacher N, Wall SA, Jung J, Damm T, Glüer CC, Scheller J, Rose-John S, Jones EY, Laurence A, Wilkie AOM, Schmidt-Arras D, Uhlig HH. Bone Res. 2020 Jun 11;8:24
•  Gut microbiota shape ‚inflamm-ageing‘ cytokines and account for age-dependent decline in DNA damage repair. Guedj A, Volman Y, Geiger-Maor A, Bolik J, Schumacher N, Künzel S, Baines JF, Nevo Y, Elgavish S, Galun E, Amsalem H, Schmidt-Arras D, Rachmilewitz J Gut. 2020 Jun;69(6):1064-1075
•  Degradome of soluble ADAM10 and ADAM17 metalloproteases. Scharfenberg F, Helbig A, Sammel M, Benzel J, Schlomann U, Peters F, Wichert R, Bettendorff M, Schmidt-Arras D, Rose-John S, Moali C, Lichtenthaler SF, Pietrzik CU, Bartsch JW, Tholey A, Becker-Pauly C Cell Mol Life Sci. 2020 Jan;77(2):331-350

2019

•  Regulation of Fibrotic Processes in the Liver by ADAM Proteases. Schmidt-Arras D, Rose-John S Cells. 2019 Oct 9;8(10):1226

2018

•  Early heme oxygenase 1 induction delays tumour initiation and enhances DNA damage repair in liver macrophages of Mdr2-/- mice. Barikbin R, Berkhout L, Bolik J, Schmidt-Arras D, Ernst T, Ittrich H, Adam G, Parplys A, Casar C, Krech T, Karimi K, Sass G, Tiegs G Sci Rep. 2018 Nov 2;8(1):16238
•  ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D, Oberg HH, Pecks U, van Mackelenbergh M, Weimer J, Arnold N, Maass N, Bauerschlag DO Oncotarget. 2018 Mar 23;9(22):16043-16058
• The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis. Fuchslocher Chico J, Falk-Paulsen M, Luzius A, Saggau C, Ruder B, Bolik J, Schmidt-Arras D, Linkermann A, Becker C, Rosenstiel P, Rose-John S, Adam D Oncotarget. 2018 Feb 5;9(16):12941-12958
•  ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knösel T, Gruber ES, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron AS, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand AL, Westermann J, Dempsey PJ, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S J Exp Med. 2018 Apr 2;215(4):1205-1225

2017

•  The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury. Gogoi-Tiwari J, Köhn-Gaone J, Giles C, Schmidt-Arras D, Gratte FD, Elsegood CL, McCaughan GW, Ramm GA, Olynyk JK, Tirnitz-Parker JEE J Vis Exp. 2017 Oct 21;(128):56138
•  Microbiomarkers in inflammatory bowel diseases: caveats come with caviar. Sommer F, Rühlemann MC, Bang C, Höppner M, Rehman A, Kaleta C, Schmitt-Kopplin P, Dempfle A, Weidinger S, Ellinghaus E, Krauss-Etschmann S, Schmidt-Arras D, Aden K, Schulte D, Ellinghaus D, Schreiber S, Tholey A, Rupp J, Laudes M, Baines JF, Rosenstiel P, Franke A Gut. 2017 Oct;66(10):1734-1738
•   A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis. Schwerd T, Twigg SRF, Aschenbrenner D, Manrique S, Miller KA, Taylor IB, Capitani M, McGowan SJ, Sweeney E, Weber A, Chen L, Bowness P, Riordan A, Cant A, Freeman AF, Milner JD, Holland SM, Frede N, Müller M, Schmidt-Arras D, Grimbacher B, Wall SA, Jones EY, Wilkie AOM, Uhlig HH J Exp Med. 2017 Sep 4;214(9):2547-2562
•  Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Tsitsipatis D, Jayavelu AK, Müller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schnöder TM, Heidel F, Böhmer FD Oncotarget. 2017 Apr 18;8(16):26613-26624
•  IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Bergmann J, Müller M, Baumann N, Reichert M, Heneweer C, Bolik J, Lücke K, Gruber S, Carambia A, Boretius S, Leuschner I, Becker T, Rabe B, Herkel J, Wunderlich FT, Mittrücker HW, Rose-John S, Schmidt-Arras D. Hepatology. 2017 Jan;65(1):89-103

2016

•  Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. Heim D, Gil-Ibanez I, Herden J, Parplys AC, Borgmann K, Schmidt-Arras D, Lohse AW, Rose-John S, Wege H. Oncotarget. 2016 Aug 23;7(34):55639-55648
•  Tetraspanin 8 is an interactor of the metalloprotease meprin β within tetraspanin-enriched microdomains. Schmidt F, Müller M, Prox J, Arnold P, Schönherr C, Tredup C, Minder P, Ebsen H, Janssen O, Annaert W, Pietrzik C, Schmidt-Arras D, Sterchi EE, Becker-Pauly C. Biol Chem. 2016 Sep 1;397(9):857-69
•  A disintegrin and metalloprotease 10 (ADAM10) is a central regulator of murine liver tissue homeostasis. Müller M, Wetzel S, Köhn-Gaone J, Chalupsky K, Lüllmann-Rauch R, Barikbin R, Bergmann J, Wöhner B, Zboda­kova O, Leuschner I, Martin G, Tiegs G, Rose-John S, Sedlacek R, Tirnitz-Parker JE, Saftig P, Schmidt-Arras D. Oncotarget. 2016 Apr 5;7(14):17431-41

•  IL-6 pathway in the liver: From physiopathology to therapy. Schmidt-Arras D, Rose-John S. J Hepatol. 2016 Jun;64(6):1403-15. Review.

2014

•  Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability. Cayla M, Rachidi N, Leclercq O, Schmidt-Arras D, Rosenqvist H, Wiese M, Späth GF. PLoS Pathog. 2014 Sep 18;10(9):e1004347
•  Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor α ectodomain shedding. Schwarz J, Schmidt S, Will O, Koudelka T, Köhler K, Boss M, Rabe B, Tholey A, Scheller J, Schmidt-Arras D, Schwake M, Rose-John S, Chalaris A. J Biol Chem. 2014 Jan 31;289(5):3080-93
•  Oncogenic deletion mutants of gp130 signal from intracellular compartments. Schmidt-Arras D, Müller M, Stevanović M, Horn S, Schütt A, Bergmann J, Wilkens R, Lickert A, Rose-John S. J Cell Sci. 2014 Jan 15;127(Pt 2):341-53

2013

•  Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells. Burghardt S, Erhardt A, Claass B, Huber S, Adler G, Jacobs T, Chalaris A, Schmidt-Arras D, Rose-John S, Karimi K, Tiegs G. J Immunol. 2013 Dec 1;191(11):5574-82
•  Short-term TNFα shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17. Schwarz J, Broder C, Helmstetter A, Schmidt S, Yan I, Müller M, Schmidt-Arras D, Becker-Pauly C, Koch-Nolte F, Mittrücker HW, Rabe B, Rose-John S, Chalaris A. Biochim Biophys Acta. 2013 Dec;1833(12):3355-3367
•  gp130 activation is regulated by D2-D3 interdomain connectivity. Schütt A, Zacharias M, Schneider N, Horn S, Grötzinger J, Rose-John S, Schmidt-Arras D. Biochem J. 2013 Mar 15;450(3):487-96

2012

•  Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10. Prox J, Willenbrock M, Weber S, Lehmann T, Schmidt-Arras D, Schwanbeck R, Saftig P, Schwake M. Cell Mol Life Sci. 2012 Sep;69(17):2919-32
•  Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Chalaris A, Schmidt-Arras D, Yamamoto K, Rose-John S. Dig Dis. 2012;30(5):492-9
•  The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms. Horjales S, Schmidt-Arras D, Limardo RR, Leclercq O, Obal G, Prina E, Turjanski AG, Späth GF, Buschiazzo A. Structure. 2012 Oct 10;20(10):1649-60

2011

•  The pro- and anti-inflammatory properties of the cytokine interleukin-6. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. Biochim Biophys Acta. 2011 May;1813(5):878-88
•  Adaptation of a 2D in-gel kinase assay to trace phosphotransferase activities in the human pathogen Leishmania donovani. Schmidt-Arras D, Leclercq O, Gherardini PF, Helmer-Citterich M, Faigle W, Loew D, Späth GF. J Proteomics. 2011 Aug 24;74(9):1644-51

2010

•  Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability. Yau WL, Blisnick T, Taly JF, Helmer-Citterich M, Schiene-Fischer C, Leclercq O, Li J, Schmidt-Arras D, Morales MA, Notredame C, Romo D, Bastin P, Späth GF. PLoS Negl Trop Dis. 2010 Jun 29;4(6):e729

2009

•  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Böhmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Müller-Tidow C, Mann M, Serve H. Mol Cell. 2009 Oct 23;36(2):326-39
•  Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Schmidt-Arras D, Böhmer SA, Koch S, Müller JP, Blei L, Cornils H, Bauer R, Korasikha S, Thiede C, Böhmer FD. Blood. 2009 Apr 9;113(15):3568-76

2007

•  Cellular inhibition of protein tyrosine phosphatase 1B by uncharged thioxothiazolidinone derivatives. Stuible M, Zhao L, Aubry I, Schmidt-Arras D, Böhmer FD, Li CJ, Tremblay ML. Chembiochem. 2007 Jan 22;8(2):179-86

2005

•  Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Schmidt-Arras DE, Böhmer A, Markova B, Choudhary C, Serve H, Böhmer FD. Mol Cell Biol. 2005 May;25(9):3690-703
•  Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1. Imhof D, Wieligmann K, Hampel K, Nothmann D, Zoda MS, Schmidt-Arras D, Zacharias M, Böhmer FD, Reissmann S. J Med Chem. 2005 Mar 10;48(5):1528-39

2004

•  Flt3 receptor tyrosine kinase as a drug target in leukemia. Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H. Curr Pharm Des. 2004;10(16):1867-83. Review.

2003

•  Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC. Br J Haematol. 2003 Dec;123(5):869-78